The complaint alleges that Zoetis violated the Securities Exchange Act by issuing false and misleading statements regarding its core product performance. Specifically, the suit highlights weakening prescription growth for the Librela medication following FDA safety warnings about neurological complications in dogs. Furthermore, the company reportedly lost significant market share across its portfolio, including its Trio, Apoquel, and Cytopoint product lines, to emerging competitive treatments.

Brian Schall, lead attorney at the Los Angeles-based firm, is inviting affected shareholders to discuss their legal standing and potential participation in the litigation. As the class has not yet been certified, shareholders currently remain absent class members and retain the right to take individual action or join the collective effort to recover damages incurred when the market reacted to these disclosures.